

Pharmacy Medical Necessity Guidelines: Entresto™ (sacubitril/valsartan)

Effective: October 15, 2019

Prior Authorization Required	√	Type of Review – Care Management	
Not Covered		Type of Review – Clinical Review	√
Pharmacy (RX) or Medical (MED) Benefit	RX	Department to Review	RXUM
<p>These pharmacy medical necessity guidelines apply to the following:</p> <p>Commercial Products</p> <input type="checkbox"/> Tufts Health Plan Commercial products – large group plans <input type="checkbox"/> Tufts Health Plan Commercial products – small group and individual plans <input type="checkbox"/> Tufts Health Freedom Plan products – large group plans <input type="checkbox"/> Tufts Health Freedom Plan products – small group plans <ul style="list-style-type: none"> CareLinkSM – Refer to CareLink Procedures, Services and Items Requiring Prior Authorization <p>Tufts Health Public Plans Products</p> <input type="checkbox"/> Tufts Health Direct – A Massachusetts Qualified Health Plan (QHP) (a commercial product) <input checked="" type="checkbox"/> Tufts Health Together – MassHealth MCO Plan and Accountable Care Partnership Plans <input type="checkbox"/> Tufts Health RITogether – A Rhode Island Medicaid Plan		<p>Fax Numbers: RXUM: 617.673.0988</p>	

Note: This guideline does not apply to Medicare Members (includes dual eligible Members).

OVERVIEW

FDA-APPROVED INDICATIONS

Entresto is a combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker (ARB), indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.

The 2016 American College of Cardiology/American Heart Association/Heart Failure Society of American (ACC/AHA/HFSA) heart failure guidelines recommend combining evidence-based beta blockers with an angiotensin converting enzyme (ACE) inhibitor, ARB, or an angiotensin receptor-neprilysin inhibitor (ARNI) in patients with chronic heart failure with reduced ejection fraction (HFrEF) to reduce morbidity and mortality.

COVERAGE GUIDELINES

The plan may authorize coverage of Entresto (sacubitril/valsartan) for Members when **all** of the following criteria are met:

- The prescriber is a cardiologist or is prescribing in consultation with a cardiologist
AND
- Documented diagnosis of chronic heart failure (NYHA Class II-IV) and reduced ejection fraction
AND
- The Member is not concomitantly taking an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB)

LIMITATIONS

None

CODES

None

REFERENCES

- Entresto prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation.; November 2018.
- Butler J, Fonarow GC, Zile MR et al. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail. 2014; 2(2):97-112.
- Clinicaltrials.gov. Efficacy and safety of LCZ696 Compared to valsartan, on morbidity and mortality in heart failure patients with preserved ejection fraction (PARAGON-HF). URL: <https://www.clinicaltrials.gov/ct2/show/NCT01920711?term=valsartan+heart+failure&rank=4>. Available from Internet. Accessed 2015 May 18.
- Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345(23):1667-75.

5. Corlanor prescribing information. Thousand Oaks, CA: Amgen Inc.; 2015 April.
6. Dicipinigitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. *Chest*. 2006; 129 (1 Suppl):169S-73S.
7. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. *N Engl J Med*. 1997; 336(8):525-33.
8. Elliott WJ. Drug interactions and drugs that affect blood pressure. *J Clin Hypertens*. 2006; 8(10):731-7.
9. Flather MD, Yusuf S, Kober L et al. Long-term ACE inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. *Lancet*. 2000; 355(9215):1575-81.
10. Food and Drug Administration. FDA approves Corlanor to treat heart failure. 2015c April 15. URL: <http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm442978.htm>. Available from Internet. Accessed 2015 May 6.
11. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2008; 372(9641):807-16.
12. Fox K, Ford I, Steg PG et al. Ivabradine in stable coronary artery disease without clinical heart failure. *N Engl J Med*. 2014; 371(12):1091-9.
13. Fu M, Zhou J, Sun A et al. Efficacy of ACE inhibitors in chronic heart failure with preserved ejection fraction – a meta analysis of 7 prospective clinical studies. *Int J Cardiol*. 2012; 155(1):33-8.
14. Galli A, Lombardi F. Nephilysin inhibition for heart failure. *N Engl J Med*. 2014; 371(24):2335.
15. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. *JAMA*. 1995; 273(18):1450-6.
16. Guo X, Tang P, Liu P et al. Meta-analysis of the association between two neprilysin gene polymorphisms and Alzheimer's disease. *J Neurol Sci*. 2014; 346 (1-2):6-10.
17. Heran BS, Musini VM, Bassett K et al. Angiotensin receptor blockers for heart failure. *Cochrane Database Syst Rev*. 2012; 4:CD003040.
18. Huttenrauch M, Baches S, Gerth J et al. Nephilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease. *J Alzheimers Dis*. 2015; 44(4):1291-302.
19. Manohar P, Pina IL. Therapeutic role of angiotensin II receptor blockers in the treatment of heart failure. *Mayo Clinic Proc*. 2003; 78(3):334-338
20. McDonagh EM, Boukouvala S, Aklillu E et al. PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2. *Pharmacogenet Genomics*. 2014; 24(8):409-25.
21. McMurray JJV, Packer M, Desai AS et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med*. 2014a; 371(11):993-1004.
22. Pfeffer MA, Braunwald E, Moya LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med*. 1992; 327(10):669-77.
23. Pfeffer MA, McMurray JJV, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular ejection fraction, or both. *N Engl J Med*. 2003; 349(20):1893-1906.
24. Zouein FA, de Castro Bras LE, da Costa DV et al. Heart failure with preserved ejection fraction: emerging drug strategies. *J Cardiovasc Pharmacol*. 2013; 62(1):13-21.
25. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure. *Circulation*. 2016.

APPROVAL HISTORY

October 06, 2015: Reviewed by Pharmacy & Therapeutics Committee.

Subsequent endorsement date(s) and changes made:

1. October 18, 2016: Combined criteria for Together and Commercial. Together criteria updated to include that Member is not taking an ARB.
2. April 11, 2017: Administrative update. Effective 6/1/2017, Medical Necessity Guideline applies to Tufts Health RITogether.
3. November 14, 2017: No changes
4. June 12, 2018: Updated criteria to allow prescriber to be a cardiologist or prescribing in consultation with a cardiologist.
5. March 12, 2019: Administrative update, remove Commercial and Direct from MNG. Administrative changes made to template.
6. October 15, 2019: Effective 10/15/19, retired MNG as Entresto is moving from Prior Authorization to Covered.

BACKGROUND, PRODUCT AND DISCLAIMER INFORMATION

Pharmacy Medical Necessity Guidelines have been developed for determining coverage for plan benefits and are published to provide a better understanding of the basis upon which coverage decisions are made. The plan makes coverage decisions on a case-by-case basis considering the individual member's health care needs. Pharmacy Medical Necessity Guidelines are developed for selected therapeutic classes or drugs found to be safe, but proven to be effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in the service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. The plan revises and updates Pharmacy Medical Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions.

For self-insured plans, coverage may vary depending on the terms of the benefit document. If a discrepancy exists between a Pharmacy Medical Necessity Guideline and a self-insured Member's benefit document, the provisions of the benefit document will govern.

Treating providers are solely responsible for the medical advice and treatment of members. The use of this policy is not a guarantee of payment or a final prediction of how specific claim(s) will be adjudicated. Claims payment is subject to member eligibility and benefits on the date of service, coordination of benefits, referral/authorization and utilization management guidelines when applicable, and adherence to plan policies and procedures and claims editing logic.

[Provider Services](#)